NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer

References

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10-29; PMID:22237781
   PubMed Web of Science ®Google Scholar
• Sahu A, Iyer MK, Chinnaiyan AM. Insights into Chinese prostate cancer with RNA-seq. Cell Res 2012; 22:786-8; PMID:22453238; http://dx.doi.org/10.1038/cr.2012.50
   PubMed Web of Science ®Google Scholar
• Wolf AM, Wender RC, Etzioni RB, Thompson IM, D'Amico AV, Volk RJ, Brooks DD, Dash C, Guessous I, Andrews K, et al. American cancer society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin 2010; 60:70-98; PMID:20200110
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014; 65(2):467-79; PMID:24321502; http://dx.doi.org/10.1016/j.eururo.2013.11.002
   PubMed Web of Science ®Google Scholar
• Smith MR, Cook R, Lee KA, Nelson JB. Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer. Cancer 2011; 117:2077-85; PMID:21523719; http://dx.doi.org/10.1002/cncr.25762
   PubMed Web of Science ®Google Scholar
• Shang Y, Myers M, Brown M. Formation of the androgen receptor transcription complex. Mol Cell 2002; 9:601-10; PMID:11931767; http://dx.doi.org/10.1016/S1097-2765(02)00471-9
   PubMed Web of Science ®Google Scholar
• Mahmoud AM, Zhu T, Parray A, Siddique HR, Yang W, Saleem M, Bosland MC. Differential effects of genistein on prostate cancer cells depend on mutational status of the androgen receptor. PloS One 2013; 8:e78479; PMID:24167630; http://dx.doi.org/10.1371/journal.pone.0078479
   PubMed Web of Science ®Google Scholar
• Mazaris E, Tsiotras A. Molecular pathways in prostate cancer. Nephrourol Mon 2013; 5:792-800; PMID:24282788; http://dx.doi.org/10.5812/numonthly.9430
   PubMedGoogle Scholar
• Imberg-Kazdan K, Ha S, Greenfield A, Poultney CS, Bonneau R, Logan SK, Garabedian MJ. A genome-wide RNA interference screen identifies new regulators of androgen receptor function in prostate cancer cells. Genome Res 2013; 23:581-91; PMID:23403032; http://dx.doi.org/10.1101/gr.144774.112
   PubMed Web of Science ®Google Scholar
• Baek KH, Hong ME, Jung YY, Lee CH, Lee TJ, Park ES, Kim MK, Yoo JH, Lee SW. Correlation of AR, EGFR, and HER2 expression levels in prostate cancer: immunohistochemical analysis and chromogenic in situ hybridization. Cancer Res Treat 2012; 44:50-6; PMID:22500161; http://dx.doi.org/10.4143/crt.2012.44.1.50
   PubMed Web of Science ®Google Scholar
• Whitworth H, Bhadel S, Ivey M, Conaway M, Spencer A, Hernan R, Holemon H, Gioeli D. Identification of kinases regulating prostate cancer cell growth using an RNAi phenotypic screen. PloS One 2012; 7:e38950; PMID:22761715; http://dx.doi.org/10.1371/journal.pone.0038950
   PubMed Web of Science ®Google Scholar
• Harris WP, Mostaghel EA, Nelson PS, Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Practice Urol 2009; 6:76-85; PMID:19198621; http://dx.doi.org/10.1038/ncpuro1296
   PubMedGoogle Scholar
• Andersen RJ, Mawji NR, Wang J, Wang G, Haile S, Myung JK, Watt K, Tam T, Yang YC, Bañuelos CA, et al. Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 2010; 17:535-46; PMID:20541699; http://dx.doi.org/10.1016/j.ccr.2010.04.027
   PubMed Web of Science ®Google Scholar
• Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010; 375:1437-46; PMID:20398925; http://dx.doi.org/10.1016/S0140-6736(10)60172-9
   PubMed Web of Science ®Google Scholar
• Deng Y, Yao L, Chau L, Ng SS, Peng Y, Liu X, Au WS, Wang J, Li F, Ji S, et al. N-Myc downstream-regulated gene 2 (NDRG2) inhibits glioblastoma cell proliferation. Int J Cancer 2003; 106:342-7; PMID:12845671; http://dx.doi.org/10.1002/ijc.11228
   PubMed Web of Science ®Google Scholar
• Zhou RH, Kokame K, Tsukamoto Y, Yutani C, Kato H, Miyata T. Characterization of the human NDRG gene family: a newly identified member, NDRG4, is specifically expressed in brain and heart. Genomics 2001; 73:86-97; PMID:11352569; http://dx.doi.org/10.1006/geno.2000.6496
   PubMed Web of Science ®Google Scholar
• Zhang J, Li F, Liu X, Shen L, Liu J, Su J, Zhang W, Deng Y, Wang L, Liu N, et al. The repression of human differentiation-related gene NDRG2 expression by Myc via Miz-1-dependent interaction with the NDRG2 core promoter. J Biol Chem 2006; 281:39159-68; PMID:17050536; http://dx.doi.org/10.1074/jbc.M605820200
   PubMed Web of Science ®Google Scholar
• Foletta VC, Prior MJ, Stupka N, Carey K, Segal DH, Jones S, Swinton C, Martin S, Cameron-Smith D, Walder KR. NDRG2, a novel regulator of myoblast proliferation, is regulated by anabolic and catabolic factors. J Physiol 2009; 587:1619-34; PMID:19204049; http://dx.doi.org/10.1113/jphysiol.2008.167882
   PubMed Web of Science ®Google Scholar
• Li T, Hu J, He GH, Li Y, Zhu CC, Hou WG, Zhang S, Li W, Zhang JS, Wang Z, et al. Up-regulation of NDRG2 through nuclear factor-kappa B is required for Leydig cell apoptosis in both human and murine infertile testes. Biochim Biophys Acta 2012; 1822:301-13; PMID:22138128; http://dx.doi.org/10.1016/j.bbadis.2011.11.013
   PubMed Web of Science ®Google Scholar
• Liu N, Wang L, Li X, Yang Q, Liu X, Zhang J, Wu Y, Ji S, Zhang Y, Yang A, et al. N-Myc downstream-regulated gene 2 is involved in p53-mediated apoptosis. Nucleic Acids Res 2008; 36:5335-49; PMID:18689861; http://dx.doi.org/10.1093/nar/gkn504
   PubMed Web of Science ®Google Scholar
• Yao L, Zhang J, Liu X. NDRG2: a Myc-repressed gene involved in cancer and cell stress. Acta Biochim Biophys Sin (Shanghai) 2008; 40:625-35; PMID:18604454; http://dx.doi.org/10.1111/j.1745-7270.2008.00434.x
   PubMed Web of Science ®Google Scholar
• Liu N, Wang L, Liu X, Yang Q, Zhang J, Zhang W, Wu Y, Shen L, Zhang Y, Yang A, et al. Promoter methylation, mutation, and genomic deletion are involved in the decreased NDRG2 expression levels in several cancer cell lines. Biochem Biophys Res Commun 2007; 358:164-9; PMID:17470364; http://dx.doi.org/10.1016/j.bbrc.2007.04.089
   PubMed Web of Science ®Google Scholar
• Lee DC, Kang YK, Kim WH, Jang YJ, Kim DJ, Park IY, Sohn BH, Sohn HA, Lee HG, Lim JS, et al. Functional and clinical evidence for NDRG2 as a candidate suppressor of liver cancer metastasis. Cancer Res 2008; 68:4210-20; PMID:18519680; http://dx.doi.org/10.1158/0008-5472.CAN-07-5040
   PubMed Web of Science ®Google Scholar
• Feng L, Xie Y, Zhang H, Wu Y. Down-regulation of NDRG2 gene expression in human colorectal cancer involves promoter methylation and microRNA-650. Biochem Biophys Res Commun 2011; 406:534-8; PMID:21352815; http://dx.doi.org/10.1016/j.bbrc.2011.02.081
   PubMed Web of Science ®Google Scholar
• Lorentzen A, Lewinsky RH, Bornholdt J, Vogel LK, Mitchelmore C. Expression profile of the n-myc downstream regulated gene 2 (NDRG2) in human cancers with focus on breast cancer. BMC cancer 2011; 11:14; PMID:21226903; http://dx.doi.org/10.1186/1471-2407-11-14
   PubMed Web of Science ®Google Scholar
• Zheng J, Li Y, Yang J, Liu Q, Shi M, Zhang R, Shi H, Ren Q, Ma J, Guo H, et al. NDRG2 inhibits hepatocellular carcinoma adhesion, migration and invasion by regulating CD24 expression. BMC cancer 2011; 11:251:1-9; PMID:21676268
   PubMedGoogle Scholar
• Yu C, Wu G, Dang N, Zhang W, Zhang R, Yan W, Zhao Y, Gao L, Wang Y, Beckwith N, et al. Inhibition of N-myc downstream-regulated gene 2 in prostatic carcinoma. Cancer Biol Ther 2011; 12:304-13; PMID:21623166; http://dx.doi.org/10.4161/cbt.12.4.16382
   PubMed Web of Science ®Google Scholar
• Gao L, Wu GJ, Liu XW, Zhang R, Yu L, Zhang G, Liu F, Yu CG, Yuan JL, Wang H, et al. Suppression of invasion and metastasis of prostate cancer cells by overexpression of NDRG2 gene. Cancer Lett 2011; 310:94-100; PMID:21741166; http://dx.doi.org/10.1016/j.canlet.2011.06.015
   PubMed Web of Science ®Google Scholar
• Bernard D, Pourtier-Manzanedo A, Gil J, Beach DH. Myc confers androgen-independent prostate cancer cell growth. J Clin Invest 2003; 112:1724-31; PMID:14660748; http://dx.doi.org/10.1172/JCI200319035
   PubMed Web of Science ®Google Scholar
• Gao L, Schwartzman J, Gibbs A, Lisac R, Kleinschmidt R, Wilmot B, Bottomly D, Coleman I, Nelson P, McWeeney S, et al. Androgen receptor promotes ligand-independent prostate cancer progression through c-Myc upregulation. PloS One 2013; 8:e63563; PMID:23704919; http://dx.doi.org/10.1371/journal.pone.0063563
   PubMed Web of Science ®Google Scholar
• Dozmorov MG, Hurst RE, Culkin DJ, Kropp BP, Frank MB, Osban J, Penning TM, Lin HK. Unique patterns of molecular profiling between human prostate cancer LNCaP and PC-3 cells. Prostate 2009; 69:1077-90; PMID:19343732; http://dx.doi.org/10.1002/pros.20960
   PubMed Web of Science ®Google Scholar
• Sramkoski RM, Pretlow TG, 2nd, Giaconia JM, Pretlow TP, Schwartz S, Sy MS, Marengo SR, Rhim JS, Zhang D, Jacobberger JW. A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim 1999; 35:403-9; PMID:10462204; http://dx.doi.org/10.1007/s11626-999-0115-4
   PubMed Web of Science ®Google Scholar
• Lee SO, Chun JY, Nadiminty N, Lou W, Feng S, Gao AC. Interleukin-4 activates androgen receptor through CBP/p300. Prostate 2009; 69:126-32; PMID:18819102; http://dx.doi.org/10.1002/pros.20865
   PubMed Web of Science ®Google Scholar
• Fahrenholtz CD, Rick FG, Garcia MI, Zarandi M, Cai RZ, Block NL, Schally AV, Burnstein KL. Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer. Proc Natl Acad Sci U S A 2014; 111:1084-9; PMID:24395797; http://dx.doi.org/10.1073/pnas.1323102111
   PubMed Web of Science ®Google Scholar
• Lee SO, Lou W, Hou M, Onate SA, Gao AC. Interleukin-4 enhances prostate-specific antigen expression by activation of the androgen receptor and Akt pathway. Oncogene 2003; 22:7981-8; PMID:12970746; http://dx.doi.org/10.1038/sj.onc.1206735
   PubMed Web of Science ®Google Scholar
• Lu S, Tan Z, Wortman M, Lu S, Dong Z. Regulation of heat shock protein 70-1 expression by androgen receptor and its signaling in human prostate cancer cells. Int J Oncol 2010; 36:459-67; PMID:20043082; http://dx.doi.org/10.3892/ijo_00000538
   PubMed Web of Science ®Google Scholar
• Lu S, Wang A, Lu S, Dong Z. A novel synthetic compound that interrupts androgen receptor signaling in human prostate cancer cells. Mol Cancer Ther 2007; 6:2057-64; PMID:17620434; http://dx.doi.org/10.1158/1535-7163.MCT-06-0735
   PubMed Web of Science ®Google Scholar
• Boulkroun S, Le Moellic C, Blot-Chabaud M, Farman N, Courtois-Coutry N. Expression of androgen receptor and androgen regulation of NDRG2 in the rat renal collecting duct. Pflugers Arch 2005; 451:388-94; PMID:16142456; http://dx.doi.org/10.1007/s00424-005-1410-x
   PubMed Web of Science ®Google Scholar
• Dong Y, Lee SO, Zhang H, Marshall J, Gao AC, Ip C. Prostate specific antigen expression is down-regulated by selenium through disruption of androgen receptor signaling. Cancer Res 2004; 64:19-22; PMID:14729601; http://dx.doi.org/10.1158/0008-5472.CAN-03-2789
   PubMed Web of Science ®Google Scholar
• Lee SO, Lou W, Nadiminty N, Lin X, Gao AC. Requirement for NF-(kappa)B in interleukin-4-induced androgen receptor activation in prostate cancer cells. Prostate 2005; 64:160-7; PMID:15678501; http://dx.doi.org/10.1002/pros.20218
   PubMed Web of Science ®Google Scholar
• Lee SO, Pinder E, Chun JY, Lou W, Sun M, Gao AC. Interleukin-4 stimulates androgen-independent growth in LNCaP human prostate cancer cells. Prostate 2008; 68:85-91; PMID:18008330; http://dx.doi.org/10.1002/pros.20691
   PubMed Web of Science ®Google Scholar
• Guo Y, Ma J, Wu L, Wang Q, Li X, Li X, Zhang Y, Zhang J, Yao L, Zhang J, et al. Hyperthermia-induced NDRG2 upregulation inhibits the invasion of human hepatocellular carcinoma via suppressing ERK1/2 signaling pathway. PloS One 2013; 8:e61079; PMID:23630579; http://dx.doi.org/10.1371/journal.pone.0061079
   PubMedGoogle Scholar